Results of a large international study known as SIGNIFY showed ivabradine offered no benefit to patients who had stable coronary artery disease without clinical heart failure (CHF).
Novartis plans to soon file a new drug application with the US Food and Drug Administration (FDA) for its investigational heart failure drug LCZ696. A report showing the drug works better than enalapril to prevent adverse cardiac events was released at the European Society of Cardiology Congress in Barcelona, Spain Aug. 30 and published online in the New England Journal of Medicine (NEJM).
Researchers at the University of Leicester have developed a highly sensitive “electronic-nose” to identify the infectious bacteria Clostridium difficile that causes diarrhea, stomach cramps, and fever in patients.
Monitoring patients’ own intestinal immune responses, researchers at Yale University have identified some of the bacterial culprits driving inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis.
Having regular family meals may help protect teens from the harmful mental health effects of "cyberbullying," a new study suggests. The study was published online Sept. 1 in JAMA Pediatrics.
The quality of Americans' diets has improved somewhat but remains poor overall, and dietary disparity between the rich and poor is growing, a new study shows. Education also played a role in dietary quality, which was lowest and improved more slowly among people who had 12 years or less of school, according to the study published online Sept. 1 in JAMA Internal Medicine.
New research suggests that oral immunotherapy may trigger anaphylaxis in an unusually high percentage of asthmatic teenagers with high-risk food allergies who failed to adhere to their management plan.
For patients with ST-segment elevation myocardial infarction, prehospital administration of ticagrelor is not associated with improved coronary reperfusion, according to a study published online Sept. 1 in the New England Journal of Medicine. The study was published to coincide with the annual European Society of Cardiology Congress, held from Aug. 30 to Sept. 3 in Barcelona, Spain.
For patients with stable coronary artery disease without clinical heart failure, ivabradine does not improve outcomes, according to a study published online Aug. 31 in the New England Journal of Medicine. The study was published to coincide with the annual European Society of Cardiology Congress, held from Aug. 30 to Sept. 3 in Barcelona, Spain.